Treatment Recommendations for Tardive Dyskinesia

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
Lucia RicciardiMark Edwards

Abstract

Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide recommendations on the treatment of tardive dyskinesia. We performed a systematic review of studies of the treatment of tardive dyskinesia. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. Overall level of evidence classifications and grades of recommendation were made using the Scottish Intercollegiate Guidelines Network framework. Preventing tardive dyskinesia is of primary importance, and clinicians should follow best practice for prescribing antipsychotic medication, including limiting the prescription for specific indications, using the minimum effective dose, and minimising the duration of therapy. The first-line management of tardive dyskinesia is the withdrawal of antipsychotic medication if clinically feasible. Yet, for many patients with serious mental illness, the discontinuation of antipsychotics is not possible due to disease relapse. Switching from a first-generation to a second-generation antipsychotic with a lower D2 affinity, such as clozapine or quetiapine, may b...Continue Reading

References

Jan 1, 1992·Schizophrenia Bulletin·R Yassa, D V Jeste
Oct 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerD C Moore
Jan 1, 1985·Psychopharmacology. Supplementum·J FleischhauerU Gilsdorf
Jan 1, 1985·Psychopharmacology. Supplementum·J M KaneJ Lieberman
Apr 1, 1982·Archives of General Psychiatry·J M Kane, J M Smith
Feb 1, 1983·The American Journal of Psychiatry·G Gardos, J O Cole
Jun 1, 1984·Archives of General Psychiatry·W M GlazerH Morgenstern
Sep 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·W GreilE Rüther
Jan 1, 1984·Psychopharmacology·S KorsgaardJ Gerlach
Aug 25, 1983·The New England Journal of Medicine·H SchaumburgM J Brown
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Apr 1, 1997·Journal of Clinical Psychopharmacology·S AngusN M Schneider
Jan 1, 1964·Acta Psychiatrica Scandinavica·A FaurbyeH Pakkenberg
Oct 21, 2004·The Cochrane Database of Systematic Reviews·K SoaresJ Deeks
Feb 25, 2005·International Clinical Psychopharmacology·Ya-Mei BaiChao-Cheng Lin
Dec 7, 2007·The Journal of Clinical Psychiatry·Vladimir LernerEliezer Witztum
Jul 18, 2008·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Jaspreet S BrarK N Roy Chengappa
Dec 3, 2010·Clinical Neuropharmacology·Sofia PappaSpiridon Konitsiotis
Apr 19, 2011·Handbook of Clinical Neurology·Daniel TarsyRoss J Baldessarini
Sep 13, 2011·International Review of Neurobiology·Diederik E Tenback, Peter N van Harten
Dec 6, 2011·Journal of Child and Adolescent Psychopharmacology·Tamara PringsheimScott B Patten
Dec 7, 2013·Asian Journal of Psychiatry·Nandita HazariSandeep Grover
Sep 9, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher F O'BrienJulio C Castro-Gayol
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Feb 2, 2017·The Journal of Clinical Psychiatry·Maren CarbonChristoph U Correll
Mar 23, 2017·The American Journal of Psychiatry·Robert A HauserChristopher F O'Brien
Apr 28, 2017·Neurology·Hubert H FernandezKaren E Anderson
Oct 3, 2017·Journal of Comparative Effectiveness Research·Stanley N CaroffCharles Yonan
Oct 13, 2017·The Journal of Clinical Psychiatry·Christoph U CorrellLeslie L Citrome
Nov 16, 2017·The Journal of Clinical Psychiatry·Stewart A FactorChristopher F O'Brien
Dec 17, 2017·Journal of the Neurological Sciences·Leslie Citrome
Feb 20, 2018·Journal of the Neurological Sciences·Stanley N CaroffDavid G Cunningham Owens

❮ Previous
Next ❯

Citations

Jul 7, 2020·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre J Blanchet
May 13, 2020·Drug Development Research·Miriam S MaesClement C Zai
Jul 30, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Jeane Binotto ReinheimerRoselei Fachinetto
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Min ChoeJee Wook Kim
Sep 22, 2020·Journal of the Chinese Medical Association : JCMA·Chun-Yu ChenJong-Ling Fuh
Aug 31, 2020·Medicine in Drug Discovery·Hanxiao YuWenjun Tang
Jan 9, 2021·Behavioural Brain Research·Kazunari Yoshida, Hiroyoshi Takeuchi
Apr 14, 2020·Neurologic Clinics·Hassaan H Bashir, Joseph Jankovic
Mar 31, 2021·The Journal of Dermatological Treatment·Christian ChengJohn Koo
Jul 3, 2021·Journal of Clinical Medicine·Keisuke Ueda, Kevin J Black

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
Tamara PringsheimThomas R E Barnes
Current Opinion in Psychiatry
Christian G Widschwendter, Alex Hofer
Current Opinion in Psychiatry
Christoph U Correll, Eva M Schenk
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Kate Traynor
© 2022 Meta ULC. All rights reserved